Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 7/20 | 0.65 |
| ▸ | PDE4A | P27815 | 13/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289242 | 1.00 | TNF (0.65) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6288891 | 1.00 | TNF (0.65) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6287593 | 0.86 | TNF (0.76) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4864210 | 0.86 | TNF (0.76) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6280398 | 0.86 | TNF (0.76) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6288894 | 0.85 | TNF (0.71) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6287401 | 0.85 | TNF (0.71) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4859594 | 0.85 | TNF (0.71) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6284020 | 0.83 | TNF (0.71) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6287556 | 0.83 | TNF (0.71) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0800514-B1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORP (US) | 2006-08-23 | — | — | EP | claimed |
| US-6429221-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION | CELGENE CORPORATION | 2002-08-06 | — | — | US | claimed |
| EP-3904875-B1 | METHODS FOR DETERMINING DRUG EFFICACY USING IKZF3 (AIOLOS) | CELGENE CORP (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3313818-B1 | METHODS FOR THE TREATMENT OF KAPOSI'S SARCOMA OR KSHV-INDUCED LYMPHOMA USING IMMUNOMODULATORY COMPOUNDS, AND USES OF BIOMARKERS | CELGENE CORP (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION | 2022-10-13 | — | — | US | disclosed |
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2022-08-23 | — | — | US | disclosed |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CELGENE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220026439-A1 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | Orionis Biosciences BV (BE) | 2022-01-27 | — | — | US | disclosed |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORPORATION (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3077548-B1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORP (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3904875-A1 | METHODS FOR DETERMINING DRUG EFFICACY USING IKZF3 (AIOLOS) | Celgene Corporation (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20090232796-A1 | METHOD OF TREATING CANCER BY ADMINISTERING AN IMMUNOMODULATORY COMPOUND IN COMBINATION WITH A CD40 ANTIBODY OR CD40 LIGAND | CELGENE CORPORATION | 2009-09-17 | — | — | US | disclosed |
| WO-2009085234-A2 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | SIGNAL PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090176237-A1 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090148853-A1 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA | CELGENE CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-7329761-B2 | Substituted imides | CELGENE CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050090516-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2005-04-28 | — | — | US | disclosed |
| US-6844359-B2 | Substituted imides | CELGENE CORPORATION (US) | 2005-01-18 | — | — | US | disclosed |
| US-20020143027-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2002-10-03 | — | — | US | disclosed |
| US-6429221-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION | CELGENE CORPORATION | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143027-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | TNF 1/4885PDE4A 4093/4885PDE4B 4323/4885 |
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CD79B, BCL6, CD22 | TNF 2135/4885PDE4A 4566/4885PDE4B 4638/4885 |
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | TNF 4075/4885PDE4A 3511/4885PDE4B 3182/4885 |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | BCL9, BCL9L, IKZF1 | TNF 2236/4885PDE4A 3552/4885PDE4B 4023/4885 |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CD79B, BCL6, CD22 | TNF 2135/4885PDE4A 4566/4885PDE4B 4638/4885 |
| US-20050090516-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | TNF 1/4885PDE4A 4100/4885PDE4B 4336/4885 |
| US-20090232796-A1 | METHOD OF TREATING CANCER BY ADMINISTERING AN IMMUNOMODULATORY COMPOUND IN COMBINATION WITH A CD40 ANTIBODY OR CD40 LIGAND | CD40LG, CD40, ICOS | TNF 71/4885PDE4A 3231/4885PDE4B 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.